HIV and rheumatic disease as drivers of CVD Público

Abstract

In 2018, 37,968 people received an HIV diagnosis in the United States, and an estimated 1.2 million people in the United States. had HIV at the end of 2018. Globally, 38 million people were living with HIV. Antiretroviral therapy (ART) has transformed HIV into a chronic disease. As a result, people with HIV (PWH) are surviving long enough to experience age-related diseases including cardiovascular disease (CVD). The association between CVD and HIV is well-established. Many studies have shown an increased risk of CVD for PWH. One study reported that the risk was approximately twice as high for developing CVD in PWH compared to people without HIV. Anti-inflammatory and immunomodulatory therapy for these diseases can mitigate CVD risk. However, there are few studies which have examined the incidental effect of anti-inflammatory medications on CVD for PLWH. Targeting inflammation is a plausible approach for reducing CVD risk for PWH. The present study examined the effect of anti-inflammatory and immune-modulatory therapies on CVD risk for PWH who received these treatments for a concomitant rheumatologic and/or autoimmune disease. This was a retrospective cohort study based on electronic health record (EHR) data collected from the Atlanta Veterans Affairs (VA) Health Care System. Cause-specific cox modeling was used to identify independent predictors of time to CVD. Rheumatologic therapies prescribed at any time during the follow-up period were used as nominal exposures. The outcome of interest for this study was the first occurrence of a CVD events of any kind after HIV diagnosis. Our analyses suggest that steroids and NSAIDS are associated with increased risk for CVD events in PWH while the CVD effects of immunomodulator therapies for this patient population remain to be defined. 

Table of Contents

1.Introduction -------------------------------------------------------------------------------1 

2. Background -------------------------------------------------------------------------------1 

3. Background -------------------------------------------------------------------------------1 

4. Method -------------------------------------------------------------------------------------6 

5. Result ---------------------------------------------------------------------------------------8 

6. Discussion ---------------------------------------------------------------------------------13 

7. Limitation ----------------------------------------------------------------------------------15 

8. Conclusion----------------------------------------------------------------------------------15 

9. Environmental considerations -----------------------------------------------------------15 

About this Master's Thesis

Rights statement

• Permission granted by the author to include this thesis or dissertation in this repository. All rights reserved by the author. Please contact the author for information regarding the reproduction and use of this thesis or dissertation.

School	Rollins School of Public Health
Department	Environmental Health
Degree	M.P.H.
Submission	Master's Thesis
Language	English
Research Field	Health Sciences, Public Health
Palavra-chave	hiv
Committee Chair / Thesis Advisor	Vincent Charles Marconi, MD, Emory University Boghuma Kabisen Titanji, MD, PhD, Emory University
Committee Members	Barry Ryan, PhD, Emory University

Última modificação

Primary PDF

Thumbnail	Title	Date Uploaded	Actions
	HIV and rheumatic disease as drivers of CVD ()	2021-05-08 21:53:44 -0400	Press to Select an action Download

Supplemental Files

Thumbnail	Title	Date Uploaded	Actions